Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

NCT02867592 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02867592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02867592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 18, 2017
Completion date
June 28, 2027
Enrollment
109 (actual)
Sites
142

Conditions

As the registry lists them; a condition with its own page is linked.

adrenal cortical carcinoma, alveolar soft part sarcoma, central nervous system neoplasm, childhood clear cell sarcoma of soft tissue, clear cell sarcoma of soft tissue, ewing sarcoma, hepatoblastoma, hepatocellular carcinoma, osteosarcoma, recurrent adrenal cortical carcinoma, recurrent alveolar soft part sarcoma, recurrent clear cell sarcoma of soft tissue, recurrent ewing sarcoma, recurrent hepatoblastoma, recurrent hepatocellular carcinoma, recurrent kidney wilms tumor, recurrent malignant solid neoplasm, recurrent osteosarcoma, recurrent primary malignant central nervous system neoplasm, recurrent renal cell carcinoma, recurrent rhabdomyosarcoma, recurrent soft tissue sarcoma, recurrent thyroid gland medullary carcinoma, refractory adrenal cortical carcinoma, refractory alveolar soft part sarcoma, refractory clear cell sarcoma of soft tissue, refractory ewing sarcoma, refractory hepatoblastoma, refractory hepatocellular carcinoma, refractory malignant solid neoplasm, refractory osteosarcoma, refractory primary central nervous system neoplasm, refractory primary malignant central nervous system neoplasm, refractory renal cell carcinoma, refractory rhabdomyosarcoma, refractory soft tissue sarcoma, refractory thyroid gland medullary carcinoma, refractory wilms tumor, renal cell carcinoma, rhabdomyosarcoma, soft tissue sarcoma, solid neoplasm, thyroid gland medullary carcinoma, wilms tumor